Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Perseus Proteomics, Inc. ( (JP:4882) ) has provided an announcement.
Perseus Proteomics reported net sales of ¥135 million for the year ended March 31, 2026, up 12.6% year on year, but continued to post an operating loss of ¥744 million and a net loss of ¥718 million, albeit narrower than the previous year. Total assets fell to ¥1.62 billion and shareholders’ equity ratio declined to 70.1% as cash and cash equivalents decreased to ¥1.52 billion, while the company again paid no dividend and refrained from issuing a forecast for the year to March 2027 due to difficulties in rationally estimating results.
Operating cash outflows of ¥653 million were partly offset by ¥497 million in financing inflows, signaling continued dependence on external funding as cumulative losses weigh on equity. The absence of earnings guidance, persistent negative margins, and dilution from a higher share count underscore execution and funding risks for investors, even as modest sales growth and slightly reduced losses indicate incremental operational progress.
More about Perseus Proteomics, Inc.
Perseus Proteomics, Inc. is a Japan-based biotech company listed on the Tokyo Stock Exchange that focuses on antibody-related technologies and proteomics-driven drug discovery. Its business model is centered on developing and commercializing therapeutic and diagnostic products, with revenues still modest relative to ongoing R&D and administrative expenses, reflecting an early-stage, growth-oriented profile.
Average Trading Volume: 1,056,231
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.48B
See more insights into 4882 stock on TipRanks’ Stock Analysis page.